Orlistat / Slug Cancer Research Results

OLST, Orlistat: Click to Expand ⟱
Features:

Orlistat (tetrahydrolipstatin; anti-obesity drug; OTC 60 mg, Rx 120 mg). A potent, minimally absorbed gastrointestinal lipase inhibitor that reduces dietary fat absorption (~30% at 120 mg TID).

Primary mechanisms (conceptual rank):
1) Irreversible inhibition of gastric + pancreatic lipases (↓ triglyceride hydrolysis)
2) ↓ Chylomicron formation → ↓ systemic lipid flux
3) Secondary metabolic shifts (weight loss–mediated insulin sensitivity changes)

Bioavailability / PK relevance: Very low systemic absorption (<1%); primary action is intraluminal in gut. Most systemic mechanistic cancer data derive from higher in-vitro concentrations or off-target effects (e.g., FASN inhibition).

In-vitro vs oral exposure: Many anti-cancer studies use concentrations likely exceeding achievable plasma levels from standard dosing (qualifier: high concentration only for direct tumor cytotoxicity).

Clinical evidence status: Approved for obesity; cancer evidence largely preclinical/observational; no robust oncology RCT indication.

Inhibits lipase and is used to facilitate weight loss.

Orlistat — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Fatty Acid Synthase (FASN) ↓ (high concentration only) ↔ (low FASN dependence) R/G Lipid synthesis blockade; apoptosis Well-known off-target in vitro; many tumors overexpress FASN. Clinical relevance limited by low systemic exposure.
2 Lipid availability / metabolic flux ↓ (indirect) ↓ (systemic) G Reduced lipid supply Weight-loss–mediated effect; may indirectly reduce pro-tumor metabolic signaling (insulin/IGF axis).
3 PI3K/AKT/mTOR ↓ (model-dependent) ↔ / ↓ (metabolic improvement) R/G Reduced anabolic signaling Often secondary to lipid stress or metabolic shifts; not primary gut mechanism.
4 Apoptosis (caspase activation) ↑ (high concentration only) ↔ R/G Programmed cell death Observed in cancer lines at supra-physiologic levels; translation uncertain.
5 ROS / lipid peroxidation stress ↑ (lipid stress–related; model-dependent) ↔ P/R Metabolic oxidative stress Linked to FASN inhibition; not central to approved mechanism.
6 NRF2 axis ↔ (insufficient evidence) ↔ R/G Not a dominant axis No consistent evidence of primary NRF2 modulation at therapeutic exposure.
7 Ferroptosis (lipid metabolism link) ↑ (theoretical / model-dependent) ↔ R/G Lipid vulnerability shift FASN inhibition could alter lipid composition; ferroptosis relevance remains investigational.
8 HIF-1α / Warburg coupling ↓ (indirect; metabolic improvement) ↔ G Reduced pro-growth metabolic signaling Likely secondary to weight loss and insulin reduction rather than direct tumor action.
9 Ca²⁺ signaling ↔ ↔ P/R No primary role Not a recognized mechanistic axis for orlistat.
10 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Minimal systemic exposure Low absorption limits direct anti-tumor applicability; GI side effects and fat-soluble vitamin malabsorption noted.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
Slug, transcription factor Slug: Click to Expand ⟱
Source:
Type:
Slug is well known to promote tumor progression and metastasis through the epithelial-mesenchymal transition (EMT), causing loss of cell adhesion and polarity while conferring migratory and invasive properties.
Slug/SNAI2: A transcription factor that belongs to the Snail family. It is best known for its role in regulating epithelial-to-mesenchymal transition (EMT).
Expression: Upregulation of Slug in cancers is often associated with the induction of EMT. This causes cells to lose epithelial markers (like E-cadherin) and gain mesenchymal markers, leading to increased invasiveness.
Metastatic Spread: By promoting EMT, high levels of Slug facilitate tumor cell dissemination and metastasis.
Cancer Stem Cells: There is evidence suggesting that EMT, spurred by factors like Slug, can increase the proportion of cancer stem cells (CSCs). These CSCs are thought to be key players in tumor recurrence and maintenance.

General Trend: High Slug expression in various cancers (including breast, colorectal, head and neck, and others) is frequently correlated with a more aggressive phenotype and poorer clinical outcomes.
Scientific Papers found: Click to Expand⟱
1227- OLST,    Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling
- in-vivo, CRC, NA
OS↑, Inflam↓, TumCG↓, STAT3↓, NF-kB↓, β-catenin/ZEB1↓, Slug↓, XIAP↓, CDK4↓, cycD1/CCND1↓, Bcl-2↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

XIAP↓, 1,  

Cell Death ⓘ

Bcl-2↓, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

STAT3↓, 1,   TumCG↓, 1,  

Migration ⓘ

Slug↓, 1,   β-catenin/ZEB1↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,   NF-kB↓, 1,  

Functional Outcomes ⓘ

OS↑, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Slug, transcription factor Slug
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:14  Target#:413  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page